生物标志物:技术和全球市场
Report Highlights
In 2010, the total global market for biomarkers was an estimated $13.5 billion and is expected to grow to nearly $33.3 billion by the end of 2015 at a 5-year compound annual growth rate (CAGR) of 19.8%.
Report Scope
讨论了预测期(2010年至2015年)的当前和预计产品预测。同样,FDA于2009年和2010年批准的新产品预计,预计将在预测期内获得批准。2010年是一个估计的数字,除了报告实际结果之外,由于报告的发布时间。对于所有领域,详细讨论了包括非常大的市场细分,例如传染病和心血管特定的作用机制。
该报告包括对当前全球生物标志物市场中领先和新兴竞争对手的分析。分析了领先产品的制造商以及开发新产品的生物技术公司,以定义其采用的特定产品策略。该报告还评估了准备在预测期内引入产品的公司,并讨论了这些介绍将如何改变竞争环境的面貌。对竞争环境进行了特别关注的竞争环境,重点是新产品和技术如何影响当前的护理标准。讨论了当前市场领导者的详细概况,以及具有创新产品的公司,可以在预测期内推进。
市场数字基于制造商水平的收入,预计为2010美元的价值。通胀未计算到投影图中。根据现有产品的预计销售,新产品介绍,现有产品的扩展适应症以及某些疾病的患病率,诊断和脚本率的预计变化来评估趋势。
本报告中包括的是产品,产品类别以及2009年至2015年的公司的预测。该研究已安排,概述了生物标志物市场的概述,并伴随着产品,公司,地理位置和行动机制,并进行了预测。由地理区域或国家 /地区。实际上,整个地球都涵盖了每个疾病子段的患病率数据。
Excluded from this report are over-the-counter (OTC) medications, and other consumables that do not require a physician’s prescription.
Sales figures are reported in U.S. dollars and in each case reflect currency fluctuations within the performance of revenue change. Revenue figures do not account for variation in local currencies.
All market share data presented is on a global basis, unless specifically noted.
Analyst Credentials
Jackson Highsmith is a life sciences research consultant with more than 16 years of research experience. Jackson has been consulting with specialty pharmaceuticals and large pharmaceutical industry players since 2007. Prior to that, he worked at a large research consultancy, where he focused on in-depth research; he also has worked at a large pharmaceutical company in a wide range of medical therapeutics in early- and mid-stage drug development.
Report Highlights
-
全球生物标志物市场从2006年的48亿美元增加到截至2007年底的56亿美元。到2012年,它应达到128亿美元,即18%的复合年增长率(CAGR)。
-
Global revenues for biomarker discovery technologies tailored to drug discovery, preclinical studies of drug development and diagnostics research applications accounted for 47.9% of the total market in 2007. Their value is projected to grow at a CAGR of 16.9% and is expected to reach a little less than $6 billion in 2012.
-
The use of biomarkers in oncology therapeutics is likely to be one of the foremost priorities in clinical trials in the next 3 to 7 years followed by cardiovascular applications.